BridgeBio Capital Stock vs Retained Earnings Analysis
BBIO Stock | USD 30.09 0.95 3.06% |
BridgeBio Pharma financial indicator trend analysis is way more than just evaluating BridgeBio Pharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BridgeBio Pharma is a good investment. Please check the relationship between BridgeBio Pharma Capital Stock and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
Capital Stock vs Retained Earnings
Capital Stock vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BridgeBio Pharma Capital Stock account and Retained Earnings. At this time, the significance of the direction appears to have very strong relationship.
The correlation between BridgeBio Pharma's Capital Stock and Retained Earnings is 0.84. Overlapping area represents the amount of variation of Capital Stock that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of BridgeBio Pharma, assuming nothing else is changed. The correlation between historical values of BridgeBio Pharma's Capital Stock and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Stock of BridgeBio Pharma are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Capital Stock i.e., BridgeBio Pharma's Capital Stock and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.84 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Capital Stock
The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from BridgeBio Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BridgeBio Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.At this time, BridgeBio Pharma's Issuance Of Capital Stock is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 8.3 B, while Selling General Administrative is likely to drop about 123 M.
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 5.8M | 6.8M | 6.5M | 4.2M | Total Operating Expenses | 646.3M | 546.1M | 606.3M | 442.1M |
BridgeBio Pharma fundamental ratios Correlations
Click cells to compare fundamentals
BridgeBio Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BridgeBio Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 631.7M | 703.6M | 1.0B | 623.0M | 546.4M | 641.2M | |
Other Current Liab | 4.1M | 5.6M | 113.3M | 94.4M | 123.0M | 129.1M | |
Total Current Liabilities | 52.4M | 91.9M | 130.1M | 117.8M | 143.8M | 90.7M | |
Total Stockholder Equity | 408.5M | 57.9M | (870.4M) | (1.3B) | (1.4B) | (1.3B) | |
Other Liab | 3.5M | 7.9M | 22.1M | 26.6M | 30.6M | 32.2M | |
Net Tangible Assets | 408.5M | 59.5M | (915.3M) | (1.3B) | (1.2B) | (1.1B) | |
Property Plant And Equipment Net | 5.6M | 36.8M | 46.0M | 25.2M | 19.8M | 21.3M | |
Net Debt | (264.0M) | 139.7M | 1.3B | 1.3B | 1.4B | 1.4B | |
Retained Earnings | (440.0M) | (888.8M) | (1.4B) | (1.9B) | (2.6B) | (2.4B) | |
Accounts Payable | 8.9M | 8.9M | 11.9M | 11.6M | 10.7M | 10.6M | |
Cash | 363.8M | 356.1M | 393.8M | 376.7M | 375.9M | 376.3M | |
Non Current Assets Total | 31.9M | 60.8M | 173.1M | 117.8M | 68.8M | 74.3M | |
Non Currrent Assets Other | (4.9M) | 21.3M | 33.0M | 20.2M | 22.6M | 14.8M | |
Other Assets | 26.3M | 23.9M | 33.0M | 140.8M | 161.9M | 170.0M | |
Cash And Short Term Investments | 577.1M | 607.1M | 787.5M | 428.3M | 434.9M | 528.5M | |
Common Stock Total Equity | 124K | 125K | 154K | 157K | 141.3K | 134.2K | |
Common Stock Shares Outstanding | 105.1M | 118.0M | 144.4M | 147.5M | 162.8M | 135.5M | |
Liabilities And Stockholders Equity | 631.7M | 703.6M | 1.0B | 623.0M | 546.4M | 641.2M | |
Non Current Liabilities Total | 103.3M | 503.8M | 1.7B | 1.8B | 1.7B | 1.0B | |
Other Current Assets | 22.6M | 35.7M | 101.3M | 21.9M | 24.3M | 32.8M | |
Other Stockholder Equity | 845.9M | 946.3M | 566.5M | 663.7M | 1.2B | 664.4M | |
Total Liab | 155.7M | 595.7M | 1.9B | 1.9B | 1.9B | 1.1B | |
Net Invested Capital | 500.2M | 535.2M | 833.4M | 453.0M | 372.5M | 397.1M | |
Property Plant And Equipment Gross | 5.6M | 36.8M | 46.0M | 25.2M | 19.8M | 21.3M | |
Total Current Assets | 599.8M | 642.8M | 839.7M | 505.2M | 477.6M | 566.9M | |
Accumulated Other Comprehensive Income | 254K | 192K | (132K) | (328K) | 31K | 32.6K | |
Non Current Liabilities Other | 3.5M | 24.2M | 39.5M | 26.6M | 9.4M | 16.3M | |
Net Working Capital | 508.2M | 547.2M | 709.6M | 387.4M | 333.7M | 469.5M | |
Common Stock | 124K | 125K | 154K | 157K | 181K | 172.0K | |
Property Plant Equipment | 5.6M | 20.3M | 46.0M | 14.6M | 16.8M | 16.2M | |
Short Long Term Debt Total | 99.8M | 495.8M | 1.7B | 1.7B | 1.7B | 1.1B | |
Long Term Debt | 91.8M | 475.9M | 1.7B | 1.7B | 1.7B | 1.1B | |
Long Term Debt Total | 91.8M | 475.9M | 1.7B | 1.7B | 2.0B | 2.1B | |
Capital Stock | 124K | 125K | 154K | 157K | 181K | 172.0K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is BridgeBio Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.23) | Revenue Per Share 1.291 | Quarterly Revenue Growth 114.619 | Return On Assets (0.40) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.